Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | LTA4H | P09960 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL272888 | 0.90 | ALDH1A1 (0.76) | ALDH1A1CYP3A4SMN1; SMN2TDP1TSHR | |
| SCHEMBL12594105 | 0.87 | ALDH1A1 (0.66) | ALDH1A1CYP3A4SMN1; SMN2TDP1TSHR | |
| SCHEMBL31457280 | 0.87 | ALDH1A1 (0.66) | ALDH1A1CYP3A4SMN1; SMN2TDP1TSHR | |
| SCHEMBL30368 | 0.86 | ALDH1A1 (0.70) | ALDH1A1CYP3A4SMN1; SMN2TDP1TSHR | |
| SCHEMBL29764021 | 0.86 | ALDH1A1 (0.70) | ALDH1A1CYP3A4SMN1; SMN2TDP1TSHR | |
| SCHEMBL5013387 | 0.86 | MAOA (0.56) | ALDH1A1CYP3A4LTA4HSMN1; SMN2TSHR | |
| SCHEMBL28932084 | 0.86 | GAA (0.64) | ALDH1A1CYP3A4TDP1TSHRHSD17B10 | |
| SCHEMBL1961773 | 0.85 | ALDH1A1 (0.63) | ALDH1A1CYP3A4LTA4HSMN1; SMN2TDP1 | |
| SCHEMBL3045451 | 0.85 | ALDH1A1 (0.63) | ALDH1A1CYP3A4LTA4HSMN1; SMN2TDP1 | |
| SCHEMBL5583756 | 0.85 | ALDH1A1 (0.63) | ALDH1A1CYP3A4SMN1; SMN2TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214948-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2025-07-03 | — | — | US | disclosed |
| CN-111819172-B | Triazine derivatives for the treatment of neurotrophin related diseases | 阿泽克制药公司 | 2024-02-06 | — | — | CN | disclosed |
| EP-3759088-B1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2023-01-25 | — | — | EP | disclosed |
| US-20220306589-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2022-09-29 | — | — | US | disclosed |
| CN-114846080-A | Thermoplastic molding compositions containing polyalkylene terephthalates | 巴斯夫欧洲公司 | 2022-08-02 | — | — | CN | disclosed |
| US-11352332-B2 | Triazine derivatives for treating diseases relating to neurotrophins | AlzeCure Pharma AB (SE) | 2022-06-07 | — | — | US | disclosed |
| US-20210403456-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-12-30 | — | — | US | disclosed |
| CN-111234219-B | Polyimide precursor, polyimide having crosslinked structure, and method for producing same | 宇部兴产株式会社 | 2021-05-28 | — | — | CN | disclosed |
| CN-108137806-B | Polyimide precursor, polyimide having crosslinked structure, and method for producing same | 宇部兴产株式会社 | 2021-05-28 | — | — | CN | disclosed |
| CN-111205459-B | Polyimide precursor, polyimide having crosslinked structure, and method for producing same | 宇部兴产株式会社 | 2021-05-28 | — | — | CN | disclosed |
| WO-2015086636-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-18 | — | — | WO | disclosed |
| WO-2007056215-A9 | N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF | CYTOVIA INC (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007056215-A2 | N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF | CYTOVIA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070099877-A1 | N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-7183278-B1 | Picolinamide derivative and harmful organism control agent comprising said picolinamide derivative as active component | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-02-27 | — | — | US | disclosed |
| EP-1134214-A1 | PICOLINAMIDE DERIVATIVES AND PEST CONTROLLERS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2001-09-19 | — | — | EP | disclosed |
| EP-0103541-B1 | ANTHRAQUINONE DYES, THEIR PREPARATION AND USE | CIBA-GEIGY AG (CH) | 1989-07-19 | — | — | EP | disclosed |
| US-4501592-A | Anthraquinone dyes, process for their preparation, and use thereof | CIBA-GEIGY CORPORATION (US) | 1985-02-26 | — | — | US | disclosed |
| EP-0103541-A2 | Anthraquinone dyes, their preparation and use | CIBA-GEIGY AG (CH) | 1984-03-21 | — | — | EP | disclosed |
| US-3947477-A | Process for the preparation of aminohydroxyanthraquinones | BAYER AKTIENGESELLSCHAFT (DT) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306589-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | NTRK2, BDNF, NGF | ALDH1A1 2560/4885CYP3A4 4531/4885LTA4H 2344/4885 |
| US-20250214948-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | NTRK2, BDNF, NGF | ALDH1A1 2560/4885CYP3A4 4531/4885LTA4H 2344/4885 |
| US-20210403456-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | SLC6A11, SCN1A, SCN1B | ALDH1A1 288/4885CYP3A4 247/4885LTA4H 1630/4885 |
| US-20070099877-A1 | N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP4, CASP3, API5 | ALDH1A1 1132/4885CYP3A4 344/4885LTA4H 870/4885 |
| US-11352332-B2 | Triazine derivatives for treating diseases relating to neurotrophins | NTRK2, BDNF, NGF | ALDH1A1 2164/4885CYP3A4 4426/4885LTA4H 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.